Physician profile
Bryan D Bowen
NPI 1770578072
$13,499.04
in general payments reported to CMS, 2019-2025
58 companies · $1,643 in 2025
The $1,643 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $1,846 · 2021: $2,394 · 2022: $2,226 · 2023: $2,412 · 2024: $1,479 · 2025: $1,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,244 · Education: $271 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,244.46 |
| Education | $270.98 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,918.86 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,089.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $887.98 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $779.49 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $633.12 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $607.54 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.32 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $551.31 | 2019-2020 | |
| Amgen INC. | $484.63 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $447.17 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Novartis Pharmaceuticals Corporation | $433.35 | 2020-2025 | |
| Amarin Pharma, INC. | $406.62 | 2019-2022 | |
| Astellas Pharma US INC | $393.01 | 2021-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $392.72 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $302.21 | 2019-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.